Pfizer Wins Tafamidis Approval; Now It Will Need To Build The Market
Executive Summary
Tafamidis was approved by FDA in two formulations that will be marketed as Vyndaqel and Vyndamax for the treatment of transthyretin amyloid cardiomyopathy.
You may also be interested in...
Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results
ATTR amyloidosis patients with cardiomyopathy had statistically significant functional and quality of life improvements when treated with Onpattro (patisiran) in the Phase III APOLLO-B study.
Attralus Raises $116m To Advance Amyloidosis-Clearing Pipeline
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
Pfizer Vyndaqel Launch Surprises With An Early Burst Out Of The Gate
The drug outperformed investor expectations, generating $79m in the US in its first full quarter on the market, after Pfizer had set low expectations for the initial launch.